Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial-Reference-Cited by-同舟云学术

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Published:2017-09 Issue:9 Volume:18 Page:1202-1210
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Long Georgina V,Atkinson Victoria,Cebon Jonathan S,Jameson Michael B,Fitzharris Bernie M,McNeil Catriona M,Hill Andrew G,Ribas Antoni,Atkins Michael B,Thompson John A,Hwu Wen-Jen,Hodi F Stephen,Menzies Alexander M,Guminski Alexander D,Kefford Richard,Kong Benjamin Y,Tamjid Babak,Srivastava Archana,Lomax Anna J,Islam Mohammed,Shu Xinxin,Ebbinghaus Scot,Ibrahim Nageatte,Carlino Matteo S

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

3. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N Engl J Med,2013

4. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015

5. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014

Cited by 209 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody;Immunobiology;2024-11

2. A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation;Critical Reviews in Oncology/Hematology;2024-08

3. Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response;BJC Reports;2024-06-24

5. The Expression of Forkhead Box P3 T Regulatory Lymphocytes as a Prognostic Factor in Malignant Melanomas;International Journal of Molecular Sciences;2024-06-09